+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

E

Actively Recruiting

Immunoglobulin A nephropathy IgAN is a kidney disease where immune system proteins build up in the kidneys causing inflammation. This inflammation may lead to kidney damage over time and reduce kidney function. The study is evaluating how well mezagitamab changes protein levels in the urine compared to a placebo in adults with primary IgAN. It also aims to assess the safety and tolerability of mezagitamab and how it maintains kidney function long term compared to placebo. Participants are randomly assigned to one of two groups in the main study two-thirds will receive mezagitamab injections and one-third will receive placebo injections, both given subcutaneously for about 22 weeks. Additionally, an open-label group includes participants with varying protein levels or kidney function who receive mezagitamab similarly. The entire study lasts about 2 years, with treatment for 22 weeks followed by approximately 1.5 years of observation. During the study, participants will have regular clinic visits, including monthly check-ups during the observation period. Assessments include measuring changes in urine protein levels and kidney function over time. Safety and tolerability of the study drug will also be monitored throughout the trial. Participants may continue in the study for up to 104 weeks, with ongoing evaluations to track kidney health and proteinuria.

Age: 18Years +All GendersPhase 3
186 locations
E

Actively Recruiting

Alopecia areata AA is a condition where the immune system attacks hair follicles, causing hair loss typically on the head and face but potentially on any body part. This research aims to evaluate the safety, effectiveness, and tolerability of upadacitinib tablets in adolescents and adults with severe AA. The study involves multiple phases to assess different doses of upadacitinib compared to placebo. Participants are randomly assigned to one of three treatment groups receiving either upadacitinib Dose A, Dose B, or placebo tablets daily. Those on placebo may be re-randomized to upadacitinib groups depending on their Severity of Alopecia Tool SALT score at Week 24. The study includes periods A and B lasting up to 52 weeks each, with some participants continuing treatment for up to 108 weeks in an extension phase. The trial enrolls about 1500 participants worldwide. During the study, participants take oral tablets daily and attend regular visits at clinics or hospitals. Their response to treatment is monitored through medical assessments, blood tests, questionnaires, and side effect checks. The main outcomes measured include changes in SALT scores and recording adverse events over approximately 164 weeks. Follow-up occurs for up to 30 days after the last dose to monitor safety and treatment effects.

Age: 12Years - 63YearsAll GendersPhase 3
272 locations
E

Actively Recruiting

Autosomal Dominant Polycystic Kidney Disease ADPKD is a common genetic kidney condition where fluid-filled cysts develop in the kidneys. This Phase 2 study is evaluating the safety and effectiveness of an investigational drug called ABBV-CLS-628 for adults with ADPKD. The trial aims to understand how this treatment affects kidney volume and kidney function compared to placebo. Participants are randomly assigned to one of four groups three receive different doses of ABBV-CLS-628, and one receives a placebo. Each participant gets an intravenous infusion every 4 weeks for 92 weeks. After this treatment period, participants will be followed for up to 15 additional weeks to monitor their health and any effects. During the study, participants will attend regular visits to a hospital or clinic. Researchers will perform medical assessments, blood tests, and monitor for side effects. Questionnaires will also be completed to gather information. The main outcomes measured include changes in total kidney volume and kidney function, as well as tracking any adverse events over about 118 weeks total.

Age: 18Years - 55YearsAll GendersPhase 2
91 locations
S

Actively Recruiting

Researchers are conducting a combined phase 2b and phase 3 clinical trial to study CSL300 Clazakizumab in adults with end stage kidney disease ESKD who are undergoing maintenance dialysis. The study aims to find the right dose of CSL300 and then evaluate its effects on cardiovascular outcomes and safety in people with systemic inflammation and either atherosclerotic cardiovascular disease ASCVD or diabetes. This multicenter, randomized, double-blind, placebo-controlled trial is designed to provide detailed information on the drugs impact and risks. The study is divided into two parts. Part 1 phase 2b focuses on identifying the optimal dose of CSL300 compared to a placebo over 12 weeks. Part 2 phase 3 assesses the efficacy and safety of CSL300 versus placebo on cardiovascular events such as cardiovascular death or heart attack over approximately 5 years. Participants receive intravenous doses of CSL300 or placebo. The placebo matches the CSL300 product minus the active ingredient. Participants will be monitored through regular assessments including blood tests to measure markers of inflammation like high-sensitivity C-reactive protein hs-CRP, other blood components, and drug levels. The trial tracks cardiovascular events and safety outcomes over the study period. The research team will also observe changes in several blood markers related to inflammation and cardiovascular health. The total follow-up may last up to about five years to fully capture long-term effects and safety.

Age: 18Years +All GendersPhase 2Phase 3
566 locations
S

Actively Recruiting

This research aims to assess the safety and effectiveness of deuruxolitinib in adolescents aged 12 to less than 18 years who have severe alopecia areata, characterized by 50% or greater scalp hair loss. The study includes a double-blind, randomized, placebo-controlled treatment phase followed by an open-label extension. The goal is to better understand how well deuruxolitinib works and how safe it is for this age group with significant hair loss. Participants will be randomly assigned to receive either deuruxolitinib tablets or matching placebo tablets taken orally twice daily for 24 weeks during the initial treatment period. Following this, all participants will have the opportunity to receive deuruxolitinib for an additional 52 weeks in an open-label extension phase. This design allows comparison of the drug to placebo and longer-term evaluation of the drugs effects. Throughout the study, participants will have regular assessments of their hair loss using the Severity of Alopecia Tool SALT at multiple time points up to week 24 and beyond. Safety will be closely monitored by tracking side effects, vital signs, heart tests, lab results, and physical exams. Additional measurements include patient and clinician impressions of improvement, quality of life, and mental health assessments. The total study duration can extend up to 76 weeks of treatment plus safety follow-up to fully evaluate outcomes and tolerability.

Age: 12Years - 17YearsAll GendersPhase 3
64 locations
M

Actively Recruiting

Researchers are evaluating the maximal use of ruxolitinib cream in adults and adolescents who have hidradenitis suppurativa, a chronic skin condition characterized by painful lumps. This Phase 1 interventional trial aims to study this topical treatment applied to affected skin areas to understand its safety and pharmacokinetics. Participants will apply ruxolitinib cream at a concentration of 1.5% twice daily as a thin film to affected skin areas. The study includes only one treatment group without a placebo, focusing on maximal use. The treatment period lasts up to 24 weeks, during which no other topical or systemic antibiotics for hidradenitis suppurativa will be used. During the study, participants will be regularly monitored for treatment-emergent adverse events and any events leading to interruption or discontinuation of the treatment. Researchers will also measure pharmacokinetic parameters such as peak concentration and drug exposure over time. Participants adherence to treatment and safety will be closely observed throughout the 24-week period.

Age: 12Years - 75YearsAll GendersPhase 1
21 locations